Skip to main content

Anti Angiogenesis Strategies In Cancer Therapies

Download Anti Angiogenesis Strategies In Cancer Therapies Full eBooks in PDF, EPUB, and kindle. Anti Angiogenesis Strategies In Cancer Therapies is one my favorite book and give us some inspiration, very enjoy to read. you could read this book anywhere anytime directly from your device.

Anti Angiogenesis Strategies in Cancer Therapies

Anti Angiogenesis Strategies in Cancer Therapies Book
Author : Shaker Mousa,Paul Davis
Publisher : Academic Press
Release : 2016-11-28
ISBN : 0128026731
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences. Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents Reviews FDA-approved anti-angiogenesis agents Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents Offers insight into the development of novel anti-angiogenesis agents and future direction in this area

Anti Angiogenesis Drug Discovery and Development

Anti Angiogenesis Drug Discovery and Development Book
Author : Atta-ur-Rahman,Muhammad Iqbal Choudhary
Publisher : Elsevier
Release : 2015-06-16
ISBN : 0128039647
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians. Edited and written by leading experts in angiogenesis drug development Reviews recent advances in the field, such as coverage of anti-angiogenetic drugs in ovarian cancer Reports current strategies and future outlook for anti-angiogenic therapy and cardiovascular diseases

Antiangiogenic Cancer Therapy

Antiangiogenic Cancer Therapy Book
Author : Darren W. Davis,Roy S. Herbst,James L. Abbruzzese
Publisher : CRC Press
Release : 2007-07-25
ISBN : 9781420004298
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment. Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers. This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.

Anti Angiogenesis Strategies in Cancer Therapeutics

Anti Angiogenesis Strategies in Cancer Therapeutics Book
Author : Shaker Mousa,Paul Davis
Publisher : Academic Press
Release : 2016-12-16
ISBN : 9780128025765
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

"Anti-angiogenesis Strategies in Cancer Therapeutics" provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences. Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agentsReviews FDA-approved anti-angiogenesis agentsIllustrates the value of nanotechnology in improving the utility of anti-angiogenesis agentsOffers insight into the development of novel anti-angiogenesis agents and future direction in this area

Physiologic and Pathologic Angiogenesis

Physiologic and Pathologic Angiogenesis Book
Author : Dan Simionescu,Agneta Simionescu
Publisher : BoD – Books on Demand
Release : 2017-04-05
ISBN : 9535130234
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The purpose of this book is to highlight novel advances in the field and to incentivize scientists from a variety of fields to pursue angiogenesis as a research avenue. Blood vessel formation and maturation to capillaries, arteries, or veins is a fascinating area which can appeal to multiple scientists, students, and professors alike. Angiogenesis is relevant to medicine, engineering, pharmacology, and pathology and to the many patients suffering from blood vessel diseases and cancer, among others. We are hoping that this book will become a source of inspiration and novel ideas for all.

Antiangiogenic Cancer Therapy

Antiangiogenic Cancer Therapy Book
Author : Darren W Davis,James L. Abbruzzese,Roy S Herbst,Chairman Department of Gastrointestinal Medical Oncology and Digestive Diseases James L Abbruzzese
Publisher : CRC Press
Release : 2019-08-30
ISBN : 9780367388812
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment. Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers. This volume celebrates progress made in four decades, and more importantly, it provi

Inflammation and Angiogenesis

Inflammation and Angiogenesis Book
Author : Domenico Ribatti
Publisher : Springer
Release : 2017-11-08
ISBN : 3319684485
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This book is focused on the analysis of the role played by immune cell components in the angiogenic process associated with inflammation and tumor growth. Both innate and adaptive immune cells are involved in the mechanisms of endothelial cell proliferation, migration and activation, through the production and release of a large spectrum of pro-angiogenic mediators. These may create the specific microenvironment that favors an increased rate of tissue vascularization. The link between chronic inflammation and tumorigenesis was first proposed by Rudolf Virchow in 1863 after the observation that infiltrating leukocytes are a hallmark of tumors and first established a causative connection between the lymph reticular infiltrate at sites of chronic inflammation and the development of cancer. Tumors were described as wounds that never heal and surgeons have long described the tendency of tumors to recur in healing resection margin and it has been reported that wound healing environment provides an opportunistic matrix for tumor growth. As angiogenesis is the result of a net balance between the activities exerted by positive and negative regulators, this book will also provide information on some anti-angiogenic properties of immune cells that may be utilized for a potential pharmacological use as anti-angiogenic agents in inflammation as well as in cancer. The work is written for researchers in the field and also for graduate students which approach this matter.

Angiogenesis Modulations in Health and Disease

Angiogenesis Modulations in Health and Disease Book
Author : Shaker A. Mousa,Paul J. Davis
Publisher : Springer Science & Business Media
Release : 2014-07-08
ISBN : 9400764677
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.

Metronomic Chemotherapy

Metronomic Chemotherapy Book
Author : Guido Bocci,Giulio Francia
Publisher : Springer
Release : 2014-09-04
ISBN : 3662436043
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.

Mechanisms of Angiogenesis

Mechanisms of Angiogenesis Book
Author : Matthias Clauss,Georg Breier
Publisher : Springer Science & Business Media
Release : 2004-11-22
ISBN : 9783764364595
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Is it advisable to go back from bedside to the bench? During the last decade, few topics encountered such a broad interest in bio- gy and medicine as angiogenesis. The amazing ability of the body to restore blood flow by induction of blood vessel growth as part of an adaptive process has alarmed physicians dealing with diseases in which angiogenesis is either exaggerated (as in tumors) or too slow (as in ischemic diseases of heart and brain). Not surprisingly, pro- and antiangiogenic strategies have found their way into clinical trials. For instance, for the USA, the NIH website in early 2004 displayed 38 clinical studies involving either pro- or antiangiogenic th- apies. Given the expected overwhelming wealth of clinical data, the question may be asked whether further exploration of biological mechanisms is required or whether results from the bedside are instructive enough to proceed. This question depends also on the progress of pro- and antiangiogenic clinical trials. In the following, I give a short overview about some of the progress that has been made in this field. Since Judah Folkman proposed antiangiogenic tumor therapy thirty years ago, it has become increasingly evident that agents which interfere with blood vessel formation also block tumor progression. Accordingly, antiangiogenic therapy has gained much attention as a potential adjunct to conventional c- cer therapy.

Angiogenesis Inhibitors and Stimulators

Angiogenesis Inhibitors and Stimulators Book
Author : Shaker A. Mousa
Publisher : CRC Press
Release : 2000-10
ISBN : 0987650XXX
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The regulation of blood vessel growth underlies many normal biological processes such as reproduction, development, repair and wound healing. It also is a critical feature of pathological processes such as cancer, diabetic retinopathy, macular degeneration, inflammatory arthritis and ischemic heart disease. What causes blood vessels to grow? What inhibits their growth? This book comprehensively describes the angiogenic proteins that enhance and inhibit normal and abnormal angiogenesis. It describes the potential therapeutic applications of basic fibroblast growth factor, vascular endothelial growth factor, PECAM-1 and thrombospondin as well as other factors. The book brings together information about new blood vessel formation in many organ systems and comprises an outstanding resource on the state-of-the art in angiogenesis.

The Effect of ZnMoS4 on Tumor Angiogenesis

The Effect of ZnMoS4 on Tumor Angiogenesis Book
Author : Haiwa Wu,Kent State University. Department of Biological Sciences,OhioLINK Electronic Theses and Dissertations Center
Publisher : Unknown
Release : 2014
ISBN : 0987650XXX
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Angiogenesis, new blood vessel formation from preexisting ones, provides oxygen and nutrients for cells and removes waste products, therefore, it is a key step in many physical and pathological conditions. Angiogenesis is a complex and multi-step process and the molecular mechanisms that promote its progress are still not fully understood. However, abnormal angiogenesis causes many diseases, such as tumor growth and inflammatory diseases. It has been demonstrated that angiogenesis induced by tumor cells plays a pivotal role in tumor growth and metastasis. And tumor angiogenesis is an excellent target for cancer therapy. Currently, the anti-cancer drugs based on anti-angiogenic strategies have limited efficacy, and often engender inherent or acquired resistance. Indeed, there is growing evidence to suggest that anti-angiogenic treatment of cancer using current inhibitors may trigger more invasive and metastatic tumors due to the fact that when one angiogenic signaling pathway is blocked, new signaling pathways are triggered. Therefore, we tackled the problem from a different angle by targeting copper, which is an important co-factor required for many pro-angiogenic growth factors, such as VEGF (vascular endothelial growth factor) and FGF-2 (basic fibroblast growth factor). VEGF is one of the most studied and potent pro-angiogenic factors, involved in almost all human tumors. Our study has focused on a potential role of copper through the pathway of HIF1a (hypoxia induced factor-1) regulation of VEGF. HIF1a is a critical transcription factor that up-regulates VEGF. Copper inhibits the process of HIF1a degradation and promotes stability of HIF1a. Based on this rationale, we tested a nanoparticle-based drug (ZnMoS4 NPs) developed by Dr. Song-ping Huang and designed to selectively reduce copper concentration by ion exchange. Here we show evidence that ZnMoS4 NPs reduced VEGF expression at both mRNA and protein levels in PC3 prostate cancer cells in vitro and reduced VEGF mRNA in subcutaneous PC3 tumors. Additionally, ZnMoS4 NPs reduced both VEGF and FGF-2 induced endothelial cell tube formation (a model for angiogenesis) and migration, both essential steps for angiogenesis in vivo. This suggests that copper/zinc ion exchange mediated by ZnMoS4 NPs may also act downstream of VEGF expression to prevent angiogenesis in vivo. Thus, our work supports copper exchange as an effect inhibitor of angiogenesis; and the efficacy of ZnMoS4 NPs in tumor growth inhibition warrants further study.

Tumour Angiogenesis

Tumour Angiogenesis Book
Author : R. John Bicknell,Claire E. Lewis,Napoleone Ferrara
Publisher : Oxford University Press, USA
Release : 1997
ISBN : 0987650XXX
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

It is now widely recognised that the growth of solid tumours is angiogenesis dependent. The inhibition of tumour angiogenesis offers a novel anti-cancer therapeutic strategy. In this first book to be devoted solely to tumour angiogenesis each chapter is written by leading world experts and the twenty seven chapters taken together cover all aspects of the field.

Gene Therapy for Lung Cancer by Adeno Associated Virus Mediated Expression of Angiogenesis Inhibitors in Mouse Models

Gene Therapy for Lung Cancer by Adeno Associated Virus Mediated Expression of Angiogenesis Inhibitors in Mouse Models Book
Author : Kexia Cai
Publisher : Open Dissertation Press
Release : 2017-01-27
ISBN : 9781374673618
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This dissertation, "Gene Therapy for Lung Cancer by Adeno-associated Virus-mediated Expression of Angiogenesis Inhibitors in Mouse Models" by Kexia, Cai, 蔡克瑕, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Abstract of thesis entitled GENE THERAPY FOR LUNG CANCER BY ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF ANGIOGENESIS INHIBITORS IN MOUSE MODELS submitted by Cai Ke Xia for the degree of Doctor of Philosophy at the University of Hong Kong in November 2006 Despite recent medical advances, treatment options for lung cancer are still limited to surgical resection, chemotherapy and radiation therapy. It is therefore necessary to develop new therapeutic strategies. Therapies targeting tumor angiogenesis is particularly promising, as angiogenesis is a prerequisite for the development and spread of most cancers, including lung cancer. Anti-angiogenic therapy can also be developed into gene therapy strategies, since most endogenous angiogenesis inhibitors are proteins. Targeting neovascularization in cancer treatment requires long-term drug administration. To this end, anti-angiogenic gene therapy represents a favorable strategy. In this study, several potent endogenous angiogenic inhibitors, including vasostatin, kallistatin and angiostatin are evaluated as candidates for anti-angiogenic gene therapy for lung cancer. The recombinant adeno-associated virus (rAAV) serotype 2 genomes encoding the vasostatin, kallistatin and angiostatin were packaged into rAAV pseudotype 5 vector (rAAV2/5) and used to treat lung cancer in mouse models. I have demonstrated that rAAV2/5 was more efficient in transducing Lewis lung carcinoma (LLC) cells than the AAV2/1, AAV2/2 and AAV2/8 serotypes. Intratumoral or systemic delivery of gene products mediated by rAAV2/5 was achieved after intratumoral or intratracheal administration. Tissue specific transgene expression in the lung for at least 6 months was successfully achieved by rAAV2/5 intratracheal instillation without any obvious side effects in immunocompetent mice. Biologically active vasostatin from rAAV2/5 transduced cells could suppress endothelial cell proliferation and endothelial tube formation; induce endothelial cell morphological changes and apoptosis. Conditioned medium from rAAV2/5-kallistatin transduced cells also suppressed endothelial cell proliferation. In situ rAAV2/5-vasostatin treatment significantly inhibited subcutaneous human lung adenocarcinoma (A549) xenograft growth with accompanied reduction in microvessel density, vessel maturation and increased apoptosis in tumor tissues. Similarly, rAAV2/5-vasostatin administration to lung resulted in a significant reduction of microvessel density in primary orthotopic A549 xenografts, which contributed to significant inhibition in lymph node metastases but not the primary tumor growth. In this orthotopic model, rAAV2/5-kallistatin was found to reduce tumor burden of primary tumor and lymph node metastasis without affecting serum vascular endothelial growth factor (VEGF) level. Therapeutic outcome of rAAV2/5-vasostatin and rAAV2/5-angiostatin varied considerably in a more aggressive syngeneic LLC orthotopic model, although these two therapeutic vectors showed some benefits in inhibition of tumor progression, especially when they were used in combined treatment. Finally, my study in a spontaneous pulmonary metastasis model further confirmed that the suppression of tumor-induced neovascularization by rAAV2/5-vasostatin could lead to the reduction of both primary tumor growth and spontaneous pulmonary metastases. Adjuvan

Targets in Gene Therapy

Targets in Gene Therapy Book
Author : Yongping You
Publisher : BoD – Books on Demand
Release : 2011-08-23
ISBN : 9533075406
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

This book aims at providing an up-to-date report to cover key aspects of existing problems in the emerging field of targets in gene therapy. With the contributions in various disciplines of gene therapy, the book brings together major approaches: Target Strategy in Gene Therapy, Gene Therapy of Cancer and Gene Therapy of Other Diseases. This source enables clinicians and researchers to select and effectively utilize new translational approaches in gene therapy and analyze the developments in target strategy in gene therapy.

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy Book
Author : Anonim
Publisher : Academic Press
Release : 2022-01-14
ISBN : 0323905560
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Provides the most updated reviews on anti-angiogenic drugs as chemosensitizers by leaders in the field Encompasses summarized tables and schematic diagrams in each chapter to give a clear overview on recent findings in a didactic manner Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field

Local Therapies for Glioma

Local Therapies for Glioma Book
Author : M. Westphal,J.-C. Tonn,Z. Ram
Publisher : Springer Science & Business Media
Release : 2003-08-29
ISBN : 9783211403556
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

In addition to surgery and radiotherapy, local treatment modalities for the management of brain tumours are increasingly being developed and clinically tested. This book describes for the first time basic tumour biology as well as all current procedures in progress at the most recent level of knowledge, presented by leading experts in the respective fields. Image guided resection procedures, fluorescence guided surgery, developments in interstitial radiosurgery are addressed, just as intracavitary chemotherapy and all current concepts and studies of interstitial targeted therapy. Owing to its topicality this book will remain for long the standard for this comprehensively treated subject.

Tumor Angiogenesis Regulators

Tumor Angiogenesis Regulators Book
Author : Ruben R. Gonzalez-Perez,Bo R. Rueda
Publisher : CRC Press
Release : 2013-05-09
ISBN : 1466580976
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

The emphasis of this book is on mechanisms and pathways regulating the expression and actions of classical and novel tumor angiogenesis regulators. The contributors discuss their underlying biology as well as anti-angiogenic drugs currently in use to fight different cancers. The book provides an insight on how factors such as obesity, diabetes, and other metabolic disorders can influence the development and growth of cancer. It is of significant interest not only to oncologists but also to a wide range of medical practitioners and researchers.

Angiogenesis Inhibition

Angiogenesis Inhibition Book
Author : Rüdiger Liersch,Wolfgang E. Berdel,Torsten Kessler
Publisher : Springer Science & Business Media
Release : 2009-12-24
ISBN : 9783540782810
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in this exciting field.

Anti Angiogenesis Drug Discovery and Development

Anti Angiogenesis Drug Discovery and Development Book
Author : Atta-ur- Rahman,M. Iqbal Choudhary
Publisher : Bentham Science Publishers
Release : 2011
ISBN : 1608051625
Language : En, Es, Fr & De

DOWNLOAD

Book Description :

"The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to"